2025 Chikungunya Outbreak: A Global Health Challenge

Chikungunya virus  (CHIKV) is a mosquito-borne alphavirus causing fever, severe joint pain, rash, and muscle aches, mainly transmitted by Aedes mosquitoes. As of 2025, The chikungunya outbreak centered on Indian Ocean islands has rapidly expanded to 119 countries, including temperate regions like France [1,2]. Control focuses on vector management, surveillance, healthcare readiness, and international cooperation [3,4]. Sino Biological supports research by providing recombinant CHIKV antigens and antibodies crucial for vaccine, antiviral, and diagnostic development.

Geographical Spread and 2025 Outbreak Epicenters

Up to now, the chikungunya outbreak has dramatically expanded to more than 110 countries, putting about 5.6 billion people at risk. Since the beginning of 2025, Reunion, Mayotte, and Mauritius have all reported major chikungunya outbreaks [5,6,8]. Notably, the virus has reached temperate regions earlier than before, with locally acquired cases reported in mainland France’s Grand Est and southeastern areas [8,9]. This surge is driven by multiple factors, including expanded Aedes mosquito habitats due to climate change, increased urbanization, and international travel facilitating virus spread, populations with low immunity after years without outbreaks, and challenges in early detection caused by inconsistent surveillance and limited diagnostic resources [2,4].

Current Treatment and Vaccine Options for Chikungunya Virus

As of 2025, no specific antiviral treatments for the chikungunya virus exist; care is supportive, focusing on symptom relief. Vaccine progress includes two approved options in some countries: the live-attenuated IXCHIQ vaccine for adults (with restrictions for the elderly) and the single-dose virus-like particle vaccine VIMKUNYA for ages 12 and up [8]. Neither vaccine is yet widely available globally or in China. Control relies mainly on mosquito management, early detection, and public awareness.

Sino Biological’s Role in Supporting Chikungunya Virus Research

To address the ongoing CHIKV mutant outbreak, Sino Biological swiftly initiated the development of recombinant E1 and E2 proteins (UVE/CHIKV/2024/RE/CNR_79903) along with specific antibodies, providing crucial support to researchers working on vaccine development, antiviral therapies, and immunodiagnostic assay creation. Sino Biological offers key tools such as the recombinant CHIKV E2 glycoprotein, cDNA clones, and specialized antibodies for ELISA and LFA, all produced under strict quality controls to ensure reliability.

Applications of Sino Biological’s Products in Research

Sino Biological’s products are frequently cited in reputable journals. Liu T. and Gu D. used recombinant CHIKV E2 protein (Sino Biological, 40440-V08B) in an aptamer-based TRFIA assay to study the binding affinity and specificity of novel peptides to CHIKV E2 antigens (Figure 2) [10]. Tamburini B. et al. investigated viral antigen acquisition in LEC, BEC, and FRC cells in C57BL/6 mice infected with recombinant CHIKV E2 antigen (Sino Biological, 40440-V08B) conjugated to AlexaFluor-488. They found that both LECs and a subset of FRCs acquired the CHIKV E2 protein during the treatment window (Figure 3) [11]. Lim H. and Kim K. showed that CHIKV EI/II protein or N-linked glycan mutant E proteins induced lower humoral immune responses than the full-length E protein using mouse sera in a recombinant CHIKV E2 protein (Sino Biological, 40440-V08B) pre-coated ELISA (Figure 4) [12]. Wang T. et al. reported that EILV/CHIKV-vaccinated macaques exhibited stronger neutralization titers and higher CHIKV E2 binding IgG responses in ELISA coated with recombinant CHIKV E2 protein (Sino Biological, 40440-V08B) (Figure 5) [13].